Almost certainly. Metformin, insulin and GLP-1 prescriptions all appear in the pharmacy database carriers check, which reveals the condition by inference even if the application never mentions it.
Non-disclosure is the most expensive mistake available in this category, and it rarely works.
How they find out
Pharmacy benefit databases show what you filled, when, at what dose and how often you refilled it. Underwriters read the pattern rather than the drug. A diabetes medication plus a dose change plus a second medication tells a story the application cannot hide.
Why it matters more than the diagnosis
Every policy has a contestability period, typically the first two years, during which a carrier can investigate a claim and rescind the policy over a material misstatement. An omission found then can void the policy — the exact outcome the policy existed to prevent.
The counterintuitive part
A disclosed, managed condition often rates better than an undisclosed one that surfaces mid-underwriting. The second version raises a question about everything else on the application.
The full treatment of this topic is on Diabetes.